Member Info for Laura2022

Be aware what Jim has done on WEB and CNR this last 3 weeks

Cheadle

This was the information as to why PYC could also be high up the list for grants /research fees given Petes experience

Prior to joining us, Dr Sargent held a senior management role at global consultancy business Syneos Health Inc (NASDAQ: SYNH), leading large teams of professionals and servicing a variety of clients in the biopharmaceuticals space. Among his earlier roles, Dr Sargent has also been Head of Business Development for the UK's National Institute for Health and Care Research (NIHR), leading a team supporting global life science businesses access to funding and research infrastructure in the UK.

A few people have extra /additional consultancies

Hitesh for example

Therefore I actually think it helps as PYC FAB are.in similar sectors

Did same 3 weeks ago

Been bliss as we rise to 65p+

Your words PM2022

The deal will likely now be very, very valuable at this market cap.

PM2022

Posted in: VAL

Posts: 3,273

Price: 1.80

Strong Buy

0.5% equity when listed with numerous compounds in the US????30 Oct 2024 08:19

Valirx will get the chance. In the US it could be worth 200/300/400 million on launch??

2 clinical drugs plus 2 pre clinical. Valirx can then sell into the launch and claim a few millions????

PM2022

Posted in: VAL

Posts: 3,273

Price: 1.60

Strong Buy

201 and 401 deals nearing completition30 Oct 2024 07:52

Only needs one. 201 looks very likely imo. You don't meet twice a week and put credibility on the line and bother with an extra 0.5% equity. The deal will likely now be very, very valuable at this market cap.

But with 201 nothing has changed since you were extremely bullish on val201

You're as bad as uncanny for u turns

In October you were 100% bullish on VAL

But all the things you're now negative on you were completely bullish on for the previous 2yrs and nothing has changed with any of these projects ???

Pm2022

After 2yrs of incessant bullishness what has changed?

I'm referring to this NH from your post

Thanks in advance for your reply

It was definitely a 'bury the bad news' day today and another mistake is not making it clear the 201 is not going to complete. That is now to come in the first week of 2025.

Where does it mention...today...Val201 please NH ?

That last rns said it will be deadline to Dec 31st

Prior to this, Mr Griffin served as Chairman and Chief Executive Officer at Diplomat Pharmacy Inc. (NYSE: DPLO), the largest independent specialty pharmacy and pharmacy benefit manager in the United States, until it was acquired by Optum Rx, a subsidiary of UnitedHealth Group, in February 2020. Mr Griffin also spent over five years at Anthem, Inc. (now called Elevance Health), an American health insurance provider, where he led their $40bn+ revenue Commercial and Speciality businesses, including Anthem's 14 national Blue Cross and Blue Shield Plans. Previously, Brian also spent 25 years at Medco Health Solutions, later Merck Medco, from 1988, where he was appointed to senior executive roles at several Medco subsidiaries, and he led the creation of Medco's international business.

As part of his role, Brian will also serve as Chair of the Audit Committee.

Dr. Marla Dubinsky, Chief Executive Officer of Trellus Health, said: "I am very pleased to welcome Brian to the Board of Trellus Health. Brian has extensive experience across the US managed care industry, particularly in the managed care and speciality pharmacy segments, gained over the course of his career, which is the exact skillset that we have been looking to appoint on our Board. This makes him a great fit for us as we build commercial traction and aim to improve the lives of as many people living with IBD and other chronic conditions as possible."

Brian Griffin, Non-Executive Director of Trellus Health, said: "I am passionate about services that can improve patient outcomes and lower the costs of care, and Trellus Health's solution has been proven to achieve both. I believe my experience within managed care and pharmacy sectors can help the Company as it continues to commercialise its approach to chronic condition management, and I look forward to working with the rest of the Board."

Evening Chris

Hope to see you here soon ?

Fab is really doing fabulous

To above 5%

I'm assuming with the 5-10 green boxes it's Jamrock bleating on again

So assume you've sold out Andrey , as why would you hold an investment that you believe to be rotten .?

Yes Stas

Great to see the back of the 80ps

Into the close

Simply click on their posting history

10yrs on LSE and suddenly appeared about 6mths ago